Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2018
19th World Conference on Lung Cancer
Access to all presentations that occur during the 19th World Conference on Lung Cancer in Toronto, ON
Presentation Date(s):- Sept 23 - 26, 2018
- Total Presentations: 2384
To review abstracts of the presentations below, narrow down your search by using the Filter options below, and then select the session listing of your choice. Click the "+" for a presentation to expand & view the corresponding Abstract details.
Presentations will be available 24 hours after their live presentation time
-
+
OA08 - Mesothelioma: Immunotherapy and microRNA for Diagnosis and Treatment
- Type: Oral Abstract Session
- Track: Mesothelioma
- Presentations: 8
- Coordinates: 9/24/2018, 15:15 - 16:45, Room 201 BD
-
+
OA08.01 - Long-Term Efficacy and Safety of Nivolumab in Second- or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)
15:15 - 15:25 | Presenter: Takashi Nakano
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA08.02 - DREAM - A Phase 2 Trial of Durvalumab with First Line Chemotherapy in Mesothelioma: Final Result
15:25 - 15:35 | Presenter: Anna K. Nowak
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA08.03 - Phase II Trial of Pembrolizumab (NCT02399371) In Previously-Treated Malignant Mesothelioma (MM): Final Analysis
15:35 - 15:45 | Presenter: Arpita Desai
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA08.04 - Discussant - OA 08.01, OA 08.02, OA 08.03
15:45 - 16:00 | Presenter: Thomas John
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA08.05 - Quantifying Tumour Infiltrating Lymphocytes (TILs) in Malignant Pleural Mesothelioma (MPM) -Defining the Hot, the Warm and the Cold Tumours.
16:00 - 16:10 | Author(s): Bibhusal Thapa
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA08.06 - Tumour Suppressor MicroRNAs Modulate Drug Resistance by Targeting Anti-Apoptotic Pathways in Malignant Pleural Mesothelioma (MPM)
16:10 - 16:20 | Author(s): Marissa Williams
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA08.07 - In Silico Discovery of Unannotated miRNAs in Malignant Pleural Mesothelioma Reveals Novel Tissue-of-Origin Markers
16:20 - 16:30 | Presenter: Brenda C. Minatel
- Abstract
- Presentation
Loading...IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
OA08.08 - Discussant - OA 08.05, OA 08.06, OA 08.07
16:30 - 16:45 | Presenter: Emanuela Felley-Bosco
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login.
-
+
OA09 - Prevention and Cessation
- Type: Oral Abstract Session
- Track: Prevention and Tobacco Control
- Presentations: 8
- Coordinates: 9/24/2018, 15:15 - 16:45, Room 205 BD
-
+
OA09.01 - 5As to 3As: Evolution of the Systematic Approach to Smoking Cessation in Ontario’s Regional Cancer Centres
15:15 - 15:25 | Author(s): Erin Cameron
- Abstract
- Presentation
Loading...Information from this presentation has been removed upon request of the author.
-
+
OA09.02 - Acceptance of Smoking Cessation Services in Cancer Care Ontario’s Lung Cancer Screening Pilot for People at High Risk
15:25 - 15:35 | Presenter: William Kenneth Evans
- Abstract
- Presentation
Loading...Information from this presentation has been removed upon request of the author.
-
+
OA09.03 - Discussions Between Health Professionals and Smokers About E-Cigarettes: Results from the ITC Policy Evaluation Project
15:35 - 15:45 | Presenter: Shannon Gravely
- Abstract
- Presentation
Loading...Information from this presentation has been removed upon request of the author.
-
+
OA09.04 - Discussant - OA 09.01, OA 09.02, OA 09.03
15:45 - 16:00 | Presenter: Betty Tong
- Abstract
- Presentation
No abstract available for this presentation
Information from this presentation has been removed upon request of the author.
-
+
OA09.05 - Potential Reduction in Lung Cancer Mortality in the US from 2015-2065: A Comparative Modeling Approach
16:00 - 16:10 | Presenter: Jihyoun Jeon
- Abstract
- Presentation
Loading...Information from this presentation has been removed upon request of the author.
-
+
OA09.06 - Molecular Alterations and Estimated Indoor Radon in NSCLC Patients from the French National Cancer Institute Registry: Radon France Study
16:10 - 16:20 | Presenter: Laura Mezquita
- Abstract
- Presentation
Loading...Information from this presentation has been removed upon request of the author.
-
+
OA09.07 - Association Between Outdoor Air Pollution And Lung Cancer in Female Never Smokers
16:20 - 16:30 | Presenter: Renelle L Myers
- Abstract
- Presentation
Loading...Information from this presentation has been removed upon request of the author.
-
+
OA09.08 - Discussant - OA 09.05, OA 09.06, OA 09.07
16:30 - 16:45 | Presenter: Douglas Arenberg
- Abstract
- Presentation
No abstract available for this presentation
Information from this presentation has been removed upon request of the author.
-
+
PC03 - Controversies in Management of Resectable Thymoma
- Type: Pro-Con Session
- Track: Thymoma/Other Thoracic Malignancies
- Presentations: 9
- Coordinates: 9/24/2018, 15:15 - 16:45, Room 205 AC
-
+
PC03.01 - Post-Operative Radiation Therapy or NOT: PRO
15:15 - 15:25 | Presenter: Conrad B Falkson
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PC03.02 - Post-Operative Radiation Therapy or NOT: CON
15:25 - 15:35 | Presenter: Daniel Gomez
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PC03.03 - Discussion
15:35 - 15:45
- Abstract
No abstract available for this presentation
-
+
PC03.04 - Debate on Standard Surgical Approaches - Minimally Invasive Thymectomy
15:45 - 15:55 | Presenter: Shaf Keshavjee
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PC03.05 - Debate on Standard Surgical Approaches - Open Thymectomy
15:55 - 16:05 | Presenter: Meinoshin Okumura
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PC03.06 - Discussion
16:05 - 16:15
- Abstract
No abstract available for this presentation
-
+
PC03.07 - Adjuvant Chemotherapy for Thymic Carcinoma - YES
16:15 - 16:25 | Presenter: Giulia Pasello
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PC03.08 - Adjuvant Chemotherapy for Thymic Carcinoma - NO
16:25 - 16:35 | Presenter: Sukhmani Kaur Padda
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PC03.09 - Discussion
16:35 - 16:45
- Abstract
No abstract available for this presentation
-
+
PC04 - Targeted Therapy for NSCLC
- Type: Pro-Con Session
- Track: Targeted Therapy
- Presentations: 7
- Coordinates: 9/24/2018, 15:15 - 16:45, Room 106
-
+
PC04.01 - Optimal Sequencing of EGFR TKI Therapy (Gefitinib/Erlotinib/Afatinib First versus Osimertinib First)
15:15 - 15:27 | Presenter: James Chih-Hsin Yang
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PC04.02 - Optimal Sequencing of EGFR TKI Therapy - 3rd Generation First
15:27 - 15:39 | Presenter: Karen L. Reckamp
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PC04.03 - Adjuvant Targeted Therapy for pts with Genomic Alterations - Yes
15:39 - 15:51 | Presenter: Shun Lu
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PC04.04 - Adjuvant Targeted Therapy for pts with Genomic Alterations - No
15:51 - 16:03 | Presenter: Lecia Sequist
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PC04.05 - NGS/Whole Exome Sequencing for Routine Use
16:03 - 16:15 | Presenter: Daniel S.W. Tan
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PC04.06 - Focused Panels for Molecular Profiling for Routine Use
16:15 - 16:27 | Presenter: Fernando Lopez-Rios
- Abstract
- Presentation
No abstract available for this presentation
IASLC Members: To view this content or have the option to purchase this event, click here to login.
Conference Attendees & Access Code holders: Click here to enter your Access Code. Already entered your Access Code? Please login. -
+
PC04.07 - Q&A
16:27 - 16:45
- Abstract
No abstract available for this presentation
-
+
P1.01 - Advanced NSCLC (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 112
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.01-01 - ROS1-Positive Non-Small Cell Lung Cancer: Real-World Data in Korea
16:45 - 18:00 | Presenter: Beung Chul Ahn
- Abstract
Loading... -
+
P1.01-02 - Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012
16:45 - 18:00 | Presenter: Scott J Antonia
- Abstract
Loading... -
+
P1.01-03 - Effect of Prophylactic Cranial Irradiation on Cognitive Function and QoL in NSCLC Patients at High Risk of Brain Metastases
16:45 - 18:00 | Author(s): Ana Gonzalez-Ling
- Abstract
Loading... -
+
P1.01-04 - Treatment Patterns and Overall Survival Following Biomarker Testing in Real-World Advanced NSCLC Patients
16:45 - 18:00 | Presenter: Fabrice Barlesi
- Abstract
Loading... -
+
P1.01-05 - Metformin in Combination with Crizotinib for The Treatment of EML4-ALK+ Lung Cancer.
16:45 - 18:00 | Presenter: Abigail Bland
- Abstract
Loading... -
+
P1.01-06 - Plinabulin, a Novel Immuno-Oncology Agent Mitigates Docetaxel Chemotherapy -Induced-Neutropenia and -Thrombocytopenia in NSCLC Patients.
16:45 - 18:00 | Presenter: Douglas W. Blayney
- Abstract
Loading... -
+
P1.01-07 - Immune-Related Pneumonitis in NSCLC Patients Treated with Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy
16:45 - 18:00 | Presenter: Angela Botticella
- Abstract
Loading... -
+
P1.01-08 - Hyperresponsive Disease: A New Pattern of Response in NSCLC Patients Treated by Anti-PD-1/PD-L1
16:45 - 18:00 | Presenter: Nicole Bouchard
- Abstract
Loading... -
+
P1.01-09 - Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC with PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598
16:45 - 18:00 | Presenter: Michael Boyer
- Abstract
Loading... -
+
P1.01-10 - Stage III Non-Small Cell Lung Cancer Clinical Outcomes with Surgical Resection After Definitive Neoadjuvant Chemoradiotherapy
16:45 - 18:00 | Presenter: Ilaria Caturegli
- Abstract
Loading... -
+
P1.01-11 - Named Patient Use Program for Afatinib in Advanced NSCLC with Progression on Prior Therapy: Experience from Asian Centers
16:45 - 18:00 | Author(s): Gee-Chen Chang
- Abstract
Loading... -
+
P1.01-12 - SWItch Maintenance PEmbrolizumab in Patients with Metastatic Non Small Cell Lung Cancer (SWIPE)
16:45 - 18:00 | Presenter: Haris Charalambous
- Abstract
Loading... -
+
P1.01-13 - A Study of S-1 Plus Cisplatin in Patients with Advanced Non-Small-Cell Lung Cancer
16:45 - 18:00 | Author(s): Chun-Liang Lai
- Abstract
Loading... -
+
P1.01-14 - Immunotherapy (I) for Advanced, Pre-Treated, Non-Squamous NSCLC (APNS-NSCLC). Preliminary Data of a Pooled Analysis
16:45 - 18:00 | Author(s): Davide Tassinari
- Abstract
Loading... -
+
P1.01-15 - ROS1-Rearranged Non-Small Cell Lung Cancer Is Associated with High Rate of Venous Thromboembolism: Analysis of The METROS Trial
16:45 - 18:00 | Author(s): Rita Chiari
- Abstract
Loading... -
+
P1.01-16 - First-Line Pembrolizumab With or Without Chemotherapy in PD-L1 positive NSCLC: A Network Meta-Analysis of Randomized Trials.
16:45 - 18:00 | Presenter: Mark K. Doherty
- Abstract
Loading... -
+
P1.01-17 - Immune-Related Adverse Events in Patients with Metastatic Non-Small Cell Lung Cancer: Sex Differences and Response to Therapy.
16:45 - 18:00 | Presenter: Narjust Duma
- Abstract
Loading... -
+
P1.01-18 - Immunosenescence Correlates with Progression upon PD-(L)-1 Blockade (IO) in Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.
16:45 - 18:00 | Presenter: Roberto Ferrara
- Abstract
Loading... -
+
P1.01-19 - Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer with Leptomeningeal Metastases.
16:45 - 18:00 | Presenter: Ronan Flippot
- Abstract
Loading... -
+
P1.01-20 - Phase III Study Comparing Gefitinib (G) to Gefitinib Combined with Carboplatin and Pemetrexed (GCP) for NSCLC with EGFR Mutations (NEJ009).
16:45 - 18:00 | Presenter: Tatsuro Fukuhara
- Abstract
Loading... -
+
P1.01-21 - Safety of Durvalumab Retreatment in Advanced NSCLC Patients Who Progressed Following Initial Disease Control In ATLANTIC
16:45 - 18:00 | Presenter: Marina Chiara Garassino
- Abstract
Loading... -
+
P1.01-22 - Effect of Basal Lymphopenia on Outcome of Non Small Cell Lung Cancer Patients Treated with Immunotherapy
16:45 - 18:00 | Presenter: Giulia Galli
- Abstract
Loading... -
+
P1.01-23 - High PD-L1 Expression is Less Common Than Expected Among Advanced NSCLC in Brazil. Are We Missing the Target?
16:45 - 18:00 | Presenter: Ana Caroline Zimmer Gelatti
- Abstract
Loading... -
+
P1.01-24 - Clinical Efficacy of Immunotherapy in Metastatic Non-Small Cell Lung Cancer Patients Treated with Prior Radiotherapy
16:45 - 18:00 | Presenter: Daniel Glick
- Abstract
Loading... -
+
P1.01-25 - Carboplatin and Pemetrexed Plus Bevacizumab After Failure of First-Line EGFR-TKI Therapy for NSCLC Harboring EGFR Mutation (CJLSG 0908)
16:45 - 18:00 | Presenter: Yasuhiro Goto
- Abstract
Loading... -
+
P1.01-26 - Single-Centre Experience of Clinical Outcomes for Advanced Lung Cancer Patients in Phase I Clinical Trials.
16:45 - 18:00 | Presenter: Donna Marie Graham
- Abstract
Loading... -
+
P1.01-27 - Influence of EGFR-TKIs Treatment Lines and PFS on the Emergence of T790M Mutation
16:45 - 18:00 | Presenter: Xiaorong Dong
- Abstract
Loading... -
+
P1.01-28 - Impact of Afatinib Dosing on Safety and Efficacy Real-World in Patients with EGFR Mutation-Positive Advanced NSCLC
16:45 - 18:00 | Presenter: Balazs Halmos
- Abstract
Loading... -
+
P1.01-29 - Crizotinib in Advanced Lung Adenocarcinoma Patients with ALK or ROS-1 Rearrangement: Is it the Same?
16:45 - 18:00 | Presenter: Baohui Han
- Abstract
Loading... -
+
P1.01-30 - Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients with ALK Rearrangement: A Retrospective Study and Literature Review
16:45 - 18:00 | Presenter: Baohui Han
- Abstract
Loading... -
+
P1.01-31 - Weekly Regimen of PAXUS-PM, a Novel Cremophor-Free, with Carboplatin in Patients with Advanced Non-Small-Cell Lung Cancer in Vietnam
16:45 - 18:00 | Author(s): Tuan Hang Quoc
- Abstract
Loading... -
+
P1.01-32 - A Multicenter, Open-Label, Phase II Trial of S-1 Plus Carboplatin in Advanced Non-Small Cell Lung Cancer Patients with Interstitial Lung Disease
16:45 - 18:00 | Presenter: Masaki Hanibuchi
- Abstract
Loading... -
+
P1.01-33 - Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR study)
16:45 - 18:00 | Presenter: Toshiyuki Harada
- Abstract
Loading... -
+
P1.01-34 - Docetaxel Plus Ramucirumab with Prophylactic PEG-G-CSF Support for Chemo-NaïVe Elderly NSCLC Patients: A Phase II Study (WJOG9416L)
16:45 - 18:00 | Presenter: Akito Hata
- Abstract
Loading... -
+
P1.01-35 - Tumor Volume Analysis In ALK-Rearranged NSCLC Treated with Crizotinib: Identifying an Early Marker for Clinical Outcome
16:45 - 18:00 | Presenter: Tomoyuki Hida
- Abstract
Loading... -
+
P1.01-36 - Thoracic Surgery in Non-Small Cell Lung Cancer with Epidermal Growth Factor Receptor Mutant After Tyrosine Kinase Inhibitor Therapy
16:45 - 18:00 | Presenter: Chen-Hao Hsiao
- Abstract
Loading... -
+
P1.01-37 - BPI-9016M, a Novel c-Met Inhibitor, in Pretreated Advanced Solid Tumor: Results from a First-In-Human, Phase 1, Dose-Escalation Study
16:45 - 18:00 | Presenter: Xingsheng Hu
- Abstract
Loading... -
+
P1.01-38 - A Phase II With a Lead-In Phase I Study to Examine Safety and Efficacy of Hydroxychloroquine and Gefitinib in Advanced NSCLC
16:45 - 18:00 | Presenter: Yiqing Huang
- Abstract
Loading... -
+
P1.01-39 - Cost-Effectiveness of Crizotinib Versus Chemotherapy as First-Line Treatment of ALK Positive Advanced NSCLC -- A Real World Study
16:45 - 18:00 | Presenter: Meijuan Huang
- Abstract
Loading... -
+
P1.01-40 - Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly pts with Untreated Advanced NSCLC: TORG1323
16:45 - 18:00 | Presenter: Kentaro Ito
- Abstract
Loading... -
+
P1.01-41 - A Phase 2 Study of DS-8201a in HER2-Overexpressing or -Mutated Advanced Non-Small-Cell Lung Cancer
16:45 - 18:00 | Presenter: Pasi A Jänne
- Abstract
Loading... -
+
P1.01-42 - Real-World Evaluation of Tolerability in Older Adult Patients (≥75 Years Old) with EGFR-mutated NSCLC
16:45 - 18:00 | Presenter: Shirley Xue Jiang
- Abstract
Loading... -
+
P1.01-43 - Next-Generation Sequencing in the Exploration of Genetic Heterogeneity for Lung Adenocarcinoma Patients with EGFR Activating Mutations
16:45 - 18:00 | Presenter: Ying Jin
- Abstract
Loading... -
+
P1.01-44 - Outcome of Uncommon EGFR Mutation Positive Newly Diagnosed Advanced NSCLC Patients: A Single-Centre Retrospective Analysis
16:45 - 18:00 | Presenter: Shruti Kate
- Abstract
Loading... -
+
P1.01-45 - Crizotinib Efficacy in ALK-Positive Advanced Stage Non-Small Cell Lung Cancer Patients: A Real-World Experience from Turkey
16:45 - 18:00 | Presenter: Saadettin Kılıçkap
- Abstract
Loading... -
+
P1.01-46 - Circulating Tumor DNA Analysis for Predicting Response to Osimertinib and Disease Progression in EGFR-Mutant Non-Small-Cell Lung Cancer
16:45 - 18:00 | Author(s): Chul Kim
- Abstract
Loading... -
+
P1.01-47 - Phase I/II Trial of Dasatinib and Osimertinib in Patients with Advanced EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Presenter: Chul Kim
- Abstract
Loading... -
+
P1.01-48 - Nab-Paclitaxel Plus Gemcitabine in Advanced NSCLC After Platinum-Based Chemotherapy: Final Results and Caveolin-1 Expression
16:45 - 18:00 | Presenter: Tatsunori Kiriu
- Abstract
Loading... -
+
P1.01-49 - irAE, Possible Predictive Markers for Immune Checkpoint Inhibitors
16:45 - 18:00 | Presenter: Kazutoshi Komiya
- Abstract
Loading... -
+
P1.01-50 - Real World Experience of Nivolumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC)
16:45 - 18:00 | Presenter: Doran Ksienski
- Abstract
Loading... -
+
P1.01-51 - Real world Experience of Pembrolizumab in Patients with Metastatic Nonsmall Cell Lung Cancer (mNSCLC)
16:45 - 18:00 | Presenter: Doran Ksienski
- Abstract
Loading... -
+
P1.01-52 - BR-34- Randomized Trial of Durvalumab & Tremelimumab +/- Platinum Chemotherapy in Patients with Metastatic Squamous or Non-Squamous NSCLC
16:45 - 18:00 | Presenter: Swati Kulkarni
- Abstract
Loading... -
+
P1.01-53 - Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Presenter: Lorenza Landi
- Abstract
Loading... -
+
P1.01-54 - A Phase I/Ib Study of Binimetinib (MEK162), a MEK Inhibitor Plus Carboplatin/Pemetrexed in Non-Squamous NSCLC
16:45 - 18:00 | Author(s): Donna Graham
- Abstract
Loading... -
+
P1.01-55 - Unique Genetic Profiles from Cerebrospinal Fluid Could Predict Survival of EGFR-Mutant NSCLC with Leptomeningeal Metastases
16:45 - 18:00 | Presenter: Yangsi Li
- Abstract
Loading... -
+
P1.01-56 - Concurrent Mutations in Chinese Lung Cancer Patients Carrying HER2 Genomic Aberrations
16:45 - 18:00 | Author(s): Jun Zhao
- Abstract
Loading... -
+
P1.01-58 - Variants Distribution and Heterogeneity of Outcomes to Crizotinib in ALK-Rearranged Chinese Non-Small Cell Lung Cancers
16:45 - 18:00 | Presenter: Naixin Liang
- Abstract
Loading... -
+
P1.01-59 - A Better Real World Practice for ROS1 Positive NSCLC Patients, Driven by the Targeted Next Generation Sequencing(NGS) and the Targeted TKI
16:45 - 18:00 | Author(s): Zeng Liang
- Abstract
Loading... -
+
P1.01-60 - Preventing and Treating Brain Metastases with Three First-Line EGFR-TKI in Patients with EGFR Mutation Advanced NSCLC
16:45 - 18:00 | Presenter: Chien-Chung Lin
- Abstract
Loading... -
+
P1.01-61 - Clinical Characterization of ERBB2 Exon 20 Insertions and Heterogeneity of Outcomes to Afatinib in Chinese Lung Cancers
16:45 - 18:00 | Author(s): Yi Hu
- Abstract
Loading... -
+
P1.01-62 - The Third Generation Irreversible EGFR Inhibitor HS-10296 in Advanced Non-Small Cell Lung Cancer Patients
16:45 - 18:00 | Presenter: Shun Lu
- Abstract
Loading... -
+
P1.01-63 - Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients with Non-Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Mariona Riudavets Melià
- Abstract
Loading... -
+
P1.01-64 - Impact of STK11 Co-Mutation on Outcomes Following Immunotherapy Among Patients with TP53 and KRAS Mutated Stage IV NSCLC
16:45 - 18:00 | Presenter: Melina Elpi Marmarelis
- Abstract
Loading... -
+
P1.01-65 - PII of Pemetrexed or Pemetrexed Plus Bevacizumab for Previously Untreated Elderly (>=75) Non-Squamous NSCLC (LOGIK1201)
16:45 - 18:00 | Presenter: RIICHIRO Maruyama
- Abstract
Loading... -
+
P1.01-66 - Randomized Phase II Evaluating EGFR-TKI Associated with Anti-Estrogen in Women with Non-Squamous Advanced Stage NSCLC: IFCT-1003 LADIE Trial.
16:45 - 18:00 | Presenter: Julien Mazieres
- Abstract
Loading... -
+
P1.01-67 - Clinical Relevance of ALK/ROS1 Resistance Mutations and Other Acquired Mutations Detected by Liquid Biopsy in Advanced NSCLC Patients
16:45 - 18:00 | Presenter: Laura Mezquita
- Abstract
Loading... -
+
P1.01-68 - Correlation of the Lung Immune Prognostic Index (LIPI) and PDL1 Status with Outcomes for Immune Checkpoint Inhibitors in Advanced NSCLC Patients
16:45 - 18:00 | Presenter: Laura Mezquita
- Abstract
Loading... -
+
P1.01-69 - Validation of the Lung Immune Prognostic Index (LIPI): Useful to Identify Resistance to PD-1 Checkpoint Inhibitors in Pretreated Lung Cancer
16:45 - 18:00 | Presenter: Xabier Mielgo-Rubio
- Abstract
Loading... -
+
P1.01-70 - Efficacy and Safety of Second- or Third-Line Nab-Paclitaxel + Durvalumab in Patients with Advanced NSCLC (ABOUND.2L+)
16:45 - 18:00 | Presenter: Daniel Morgensztern
- Abstract
Loading... -
+
P1.01-71 - Co-Mutations, Natural History, and Outcomes of BRAF-Mutated Non-Small Cell Lung Cancer at a Single Academic Cancer Center
16:45 - 18:00 | Presenter: Nathaniel James Myall
- Abstract
Loading... -
+
P1.01-72 - FIND Trial: A Phase II Study to Evaluate the Efficacy of the FGFR-Inhibitor Erdafitinib in FGFR-Mutated and -Translocated Squamous NSCLC
16:45 - 18:00 | Author(s): Lucia Nogova
- Abstract
Loading... -
+
P1.01-73 - Preliminary Results of the SENECA (SEcond Line NintEdanib in Non-Small Cell Lung CAncer) Trial: An Italian Experience.
16:45 - 18:00 | Author(s): Enrica Capelletto
- Abstract
Loading... -
+
P1.01-74 - MET Exon 14-Altered Lung Cancers: Central Nervous System (CNS) Metastases and Patterns of CNS Progression on MET Inhibition.
16:45 - 18:00 | Presenter: Michael Offin
- Abstract
Loading... -
+
P1.01-75 - Utility of cfDNA Testing for Acquired Resistance: The Memorial Sloan Kettering Experience with Plasma EGFR T790M Clinical Testing.
16:45 - 18:00 | Presenter: Michael Offin
- Abstract
Loading... -
+
P1.01-76 - A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
16:45 - 18:00 | Presenter: Paul K. Paik
- Abstract
Loading... -
+
P1.01-77 - Osimertinib in the First-Line Treatment of Non-Small Cell Lung Cancer Harboring Activating EGFR Mutation from Circulating Tumor DNA
16:45 - 18:00 | Presenter: Cheol-Kyu Park
- Abstract
Loading... -
+
P1.01-78 - The Incidence of Brain Metastases in ROS1-Rearranged Non-Small Cell Lung Cancer at Diagnosis and Following Progression on Crizotinib
16:45 - 18:00 | Presenter: Tejas Patil
- Abstract
Loading... -
+
P1.01-79 - CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC
16:45 - 18:00 | Presenter: Luis Paz-Ares
- Abstract
Loading... -
+
P1.01-80 - ELIOS: A Multicenter, Open-Label, Molecular Profiling Study of Patients with EGFRm and NSCLC Treated with Osimertinib
16:45 - 18:00 | Presenter: Zofia Piotrowska
- Abstract
Loading... -
+
P1.01-81 - Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789
16:45 - 18:00 | Presenter: Gregory J Riely
- Abstract
Loading... -
+
P1.01-82 - Risk of Not Receiving 2nd Line Therapy is High in EGFR mt+ pts: Real World Data of Certified Lung Cancer Centers on Treatment Sequence in EGFR mt+ pts
16:45 - 18:00 | Presenter: Julia Roeper
- Abstract
Loading... -
+
P1.01-83 - IMpower150: Impact of Chemotherapy Cycles in 1L Metastatic NSCLC in Patients Treated With Atezolizumab + Bevacizumab
16:45 - 18:00 | Presenter: Jeffrey Rothenstein
- Abstract
Loading... -
+
P1.01-84 - High Basal Serum EGF Levels Predicts Response to CIMAvax-EGF, a Therapeutic Vaccine for Advanced NSCLC
16:45 - 18:00 | Presenter: Orestes Santos Morales
- Abstract
Loading... -
+
P1.01-85 - The Prevalence of Different EGFR exon20 Mutations in 12,833 Chinese Lung Cancer Patients
16:45 - 18:00 | Presenter: Yang W. Shao
- Abstract
Loading... -
+
P1.01-86 - BTCRC-LUN15-017: Phase-Ib Study of Imprime PGG and Pembrolizumab in Stage IV NSCLC after Progression on Platinum Based Therapy
16:45 - 18:00 | Presenter: Ardaman Shergill
- Abstract
Loading... -
+
P1.01-87 - A Phase 1b Study of TRC105 In Combination with Paclitaxel/Carboplatin and Bevacizumab in Patients with Stage 4 Non-Squamous Cell Lung Cancer
16:45 - 18:00 | Author(s): Francisco Robert
- Abstract
Loading... -
+
P1.01-88 - Osimertinib Maintenance After Definitive Chemoradiation in Patients with Unresectable EGFRm-Positive Stage III NSCLC (LAURA)
16:45 - 18:00 | Presenter: Lu Shun
- Abstract
Loading... -
+
P1.01-89 - Analysis and Monitoring CTCs and ctDNA in CSF Demonstrates Clinical Concordance in Tesevatinib Treated NSCLC Patients with LM
16:45 - 18:00 | Presenter: Veena M. Singh
- Abstract
Loading... -
+
P1.01-90 - A Pilot Trial Assessing Apatinib Combined with Docetaxel (DTX) as Second-Line Chemotherapy for EGFR Negative Advanced NSCLC)
16:45 - 18:00 | Author(s): Tang Feng Lv
- Abstract
Loading... -
+
P1.01-91 - A Phase I Study of Fixed Dose Vinorelbine and Escalating Doses of Ifosfamide in First-Line Advanced Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Julian Surujballi
- Abstract
Loading... -
+
P1.01-92 - A Phase II Study of Afatinib Treatment for Elderly Patients with Previously Untreated Advanced NSCLC Harboring EGFR Mutations
16:45 - 18:00 | Presenter: Kensuke Suzuki
- Abstract
Loading... -
+
P1.01-93 - Quality of Life in Patients with Advanced NSCLC Treated in Second- or Third-Line with Nab-Paclitaxel + Durvalumab: ABOUND.2L+
16:45 - 18:00 | Author(s): Denis Talbot
- Abstract
Loading... -
+
P1.01-94 - Phase I Trial to Establish Maximum Tolerated Dose Safety and Pharmacokinetic Profile of Oral Paclitaxel
16:45 - 18:00 | Presenter: Satheesh Chiradoni Thungappa
- Abstract
Loading... -
+
P1.01-95 - Crizotinib Treatment in 29 Advanced NSCLC Chinese Patients with ROS1 Rearrangement——A Single Chinese Cancer Institute Experience
16:45 - 18:00 | Author(s): Chang Liu
- Abstract
Loading... -
+
P1.01-96 - Concurrent ALK/EGFR Alterations in Chinese Lung Cancers: Frequency, Clinical Features, and Differential Response to Therapy
16:45 - 18:00 | Presenter: Da Wu
- Abstract
Loading... -
+
P1.01-97 - Cluster Trial: Ph2 Biomarker-Integrated Study of Single Agent Alpelisib, Capmatinib, Ceritinib and Binimetinib in advNSCLC
16:45 - 18:00 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
P1.01-98 - A Phase IIIb Trial of Afatinib in EGFRm+ NSCLC: Analyses of Outcomes in Patients with Brain Metastases or Dose Reductions
16:45 - 18:00 | Presenter: Yi-Long Wu
- Abstract
Loading... -
+
P1.01-99 - Detecting HER2 Alterations by Next Generation Sequencing (NGS) in Patients with Advanced NSCLC from the United States and China
16:45 - 18:00 | Presenter: Chong-Rui Xu
- Abstract
Loading... -
+
P1.01-100 - Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients with Brain Metastases from EGFR-Mutant NSCLC
16:45 - 18:00 | Author(s): Yaoyao Zhu
- Abstract
Loading... -
+
P1.01-101 - Survival Benefit of Sequential Therapy in ALK Positive Olioprogressive NSCLC Patients After Crizotinib Resistance
16:45 - 18:00 | Presenter: Haiyan Xu
- Abstract
Loading... -
+
P1.01-102 - Retrospective Analysis of Immune Checkpoint Inhibitors in Patients with EGFR Mutated Non-Small Cell Lung Cancer in a Japanese Cohort
16:45 - 18:00 | Presenter: Tadaaki Yamada
- Abstract
Loading... -
+
P1.01-103 - Leukocyte Telomere Length as a Novel Biomarker in Advanced Lung Adenocarcinoma Patients Treated with Gefitinib
16:45 - 18:00 | Presenter: Ming Yang
- Abstract
Loading... -
+
P1.01-104 - Updated Phase I Results of Carboplatin, Pemetrexed and Exemestane in Postmenopausal Women with Metastatic Non-Squamous NSCLC
16:45 - 18:00 | Presenter: Patricia A. Young
- Abstract
Loading... -
+
P1.01-105 - Lung Cancer Patients with Concurrent EGFR and MET Mutations: A Retrospective Analysis of 29 Cases
16:45 - 18:00 | Presenter: Zhaoxia Wang
- Abstract
Loading... -
+
P1.01-106 - Pembrolizumab Randomized, Phase 1 Study in Chinese Patients with Advanced NSCLC: KEYNOTE-032.
16:45 - 18:00 | Author(s): Yuxiang Ma
- Abstract
Loading... -
+
P1.01-107 - The Impact of Anlotinib on Quality of Life in Patients with Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303)
16:45 - 18:00 | Author(s): Xiaoyan Si
- Abstract
Loading... -
+
P1.01-108 - Management of Anlotinib-Related Adverse Events: Data From ALTER 0303
16:45 - 18:00 | Author(s): Xiaoyan Si
- Abstract
Loading... -
+
P1.01-109 - Phase I Study of Apatinib Plus Gefitinib as First-Line Therapy in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Hongyun Zhao
- Abstract
Loading... -
+
P1.01-110 - Three Specific HER2 Mutations Predict Favorable Outcomes in Advanced Lung Cancer Patients Treated with Afatinib
16:45 - 18:00 | Presenter: Shen Zhao
- Abstract
Loading... -
+
P1.01-111 - EGFR exon20 Insertion Patients Treated with First-Line Chemotherapy in Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Chao Zhao
- Abstract
Loading... -
+
P1.01-112 - Osimertinib vs Standard of Care (SoC) EGFR-TKI as First-Line Treatment in Chinese Patients With EGFRm Advanced NSCLC
16:45 - 18:00 | Presenter: Caicun Zhou
- Abstract
Loading... -
+
P1.01-113 - Analysis of Clinicopathological Features and Clinical Efficacy of Crizotinib in ROS1 Positive Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Youcai Zhu
- Abstract
Loading...
-
+
P1.02 - Advocacy (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 11
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.02-01 - Imaging of Lung Cancer at the University College Hospital, Ibadan, Nigeria: Does Nuclear Medicine Have Anything to Offer?
16:45 - 18:00 | Presenter: Olusegun Akinwale Ayeni
- Abstract
Loading... -
+
P1.02-02 - ‘Listen To Your Lungs’ – An Awareness Campaign from The Marie Keating Foundation
16:45 - 18:00 | Presenter: Anne-Marie Baird
- Abstract
Loading... -
+
P1.02-04 - The EGFR Resisters Lung Cancer Group: A Patient-Driven Initiative to Understand & Improve Treatments for EGFR+ Lung Cancer
16:45 - 18:00 | Presenter: Jill Feldman
- Abstract
Loading... -
+
P1.02-03 - The Role of Lung Cancer Advocacy Organizations in Biomarker Testing
16:45 - 18:00 | Presenter: Winfield Boerckel
- Abstract
Loading... -
+
P1.02-05 - ALK Positive Lung Cancer: Patient Engagement and Partnership
16:45 - 18:00 | Author(s): Laura Greco
- Abstract
Loading... -
+
P1.02-06 - Usefulness of Workshop to Promote Communication Between Patient and Family
16:45 - 18:00 | Presenter: Kazuo Hasegawa
- Abstract
Loading... -
+
P1.02-07 - The Role of Volunteers in Quality Palliative Care Delivery for Advance Lung Cancer
16:45 - 18:00 | Presenter: Aditya Manna
- Abstract
Loading... -
+
P1.02-08 - Hope for People Living with Metastatic Lung Cancer
16:45 - 18:00 | Presenter: Aditya Manna
- Abstract
Loading... -
+
P1.02-09 - Identifying Gaps in Messaging for Biomarker Testing in the Lung Cancer Community: Need for Consistent and Actionable Messaging
16:45 - 18:00 | Presenter: Upal Basu Roy
- Abstract
Loading... -
+
P1.02-10 - "We Are Ambassadors for Survivors:" Experiences of Lung Cancer Support Group Attendees and Facilitators
16:45 - 18:00 | Presenter: Maureen Rigney
- Abstract
Loading... -
+
P1.02-11 - Lung Cancer Symptom Awareness: Findings from a Global Consumer Survey
16:45 - 18:00 | Presenter: Maureen Rigney
- Abstract
Loading...
-
+
P1.03 - Biology (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 34
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.03-01 - Association of APC Mutations with Chinese Patients Molecular Spectrum in Non-Small-Cell Lung Cancer
16:45 - 18:00 | Presenter: Shuitu Feng
- Abstract
Loading... -
+
P1.03-02 - Analysis of SMAD4 Aberrations in Chinese Patients with Non-Small-Cell Lung Cancer
16:45 - 18:00 | Presenter: Jianhui Huang
- Abstract
Loading... -
+
P1.03-03 - Molecular Characteristics of Chinese Patients with TSC2-Mutated Non-Small-Cell Lung Cancer: A Retrospective Study
16:45 - 18:00 | Presenter: Zhangzhou Huang
- Abstract
Loading... -
+
P1.03-04 - Molecular Characteristics of ALK Primary Point Mutations Non-Small-Cell Lung Cancer in Chinese Patients
16:45 - 18:00 | Author(s): Jinhuo Lai
- Abstract
Loading... -
+
P1.03-05 - Transcriptome Landscape of Lung Adenocarcinoma Patients Revealed Distinct Trajectory Patterns
16:45 - 18:00 | Presenter: Yuqing Lou
- Abstract
Loading... -
+
P1.03-06 - Molecular Landscape of FGFR1 Point Mutations in Chinese Non-Small-Cell Lung Cancer Patients: A Retrospective Study
16:45 - 18:00 | Author(s): Hong Wang
- Abstract
Loading... -
+
P1.03-07 - A Comparison of Consistency of Detecting HER2 Gene Mutations in Peripheral Blood and Tumor Tissue of Non-Small-Cell Lung Cancer Patients
16:45 - 18:00 | Presenter: Chunwei Xu
- Abstract
Loading... -
+
P1.03-08 - Detection of PTCH1 Gene Variants in Non-Small Cell Lung Cancer Patients from China
16:45 - 18:00 | Author(s): Tianwen Xu
- Abstract
Loading... -
+
P1.03-09 - ROS1 Rearrangement in Pulmonary Sarcomatoid Carcinoma: A Retrospective Study of the Real World
16:45 - 18:00 | Presenter: Chunwei Xu
- Abstract
Loading... -
+
P1.03-10 - The Molecular Spectrum of NF1 Variants in Chinese Non-Small-Cell Lung Cancer Patients
16:45 - 18:00 | Presenter: Quxia Zhang
- Abstract
Loading... -
+
P1.03-11 - Analysis of T-Cell Repertoires in Benign and Malignant Solitary Pulmonary Nodules to Evaluate Tumor Immune Microenviroment
16:45 - 18:00 | Presenter: Min Li
- Abstract
Loading... -
+
P1.03-12 - PD-L1 Expression is Predominant in CD68+ Tumor-Associated Macrophages in Stage I-III Non-Small Cell Lung Cancers
16:45 - 18:00 | Presenter: Boris Sepesi
- Abstract
Loading... -
+
P1.03-13 - eIF2β, A Subunit of Translation-Initiation Factor EIF2, as a Potential Therapeutic Target for Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Daiki Goto
- Abstract
Loading... -
+
P1.03-14 - Interaction Between Celecoxib and Cisplatin is Dependent on The p53 Status in Human NSCLC Cell Lines
16:45 - 18:00 | Author(s): Mei Jiang
- Abstract
Loading... -
+
P1.03-15 - TMS Reduced Gefitinib Resistance In NSCLCs Via Suppressing MAPK/Akt/Bcl-2 Pathway by Upregulation of miR-345 and miR-498
16:45 - 18:00 | Presenter: Ping Liu
- Abstract
Loading... -
+
P1.03-16 - Anlotinib Inhibits Angiogenesis of Refractory Advanced Non-Small Cell Lung Cancer via Blocking CCL2 Expression
16:45 - 18:00 | Author(s): Jun Lu
- Abstract
Loading... -
+
P1.03-17 - Functional Mechanism of GLDC Gene Alternative Splicing in Non-Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Yingli Yuan
- Abstract
Loading... -
+
P1.03-18 - Mechanobiology of Lung Cancer Cells: Regulation of PD-L1 Expression by Matrix Stiffness
16:45 - 18:00 | Presenter: Ayako Miyazawa
- Abstract
Loading... -
+
P1.03-19 - Antibody Blockade of Integrin Alpha-V-Beta-6 (avb6) as a Novel Treatment for NSCLC
16:45 - 18:00 | Presenter: Banu Rudran
- Abstract
Loading... -
+
P1.03-20 - The Novel SFN Inhibitors Aprepitant and Ticagrelor Exert Anti-Tumor Effects Through Blocking of Oncoprotein Ubiquitination
16:45 - 18:00 | Presenter: Aya Shiba
- Abstract
Loading... -
+
P1.03-21 - Huaier Aqueous Extract Induces Lung Adenocarcinoma Cell Apoptosis Through Excessive Activation Of MEK/ERK Signaling Pathway
16:45 - 18:00 | Presenter: Zhao Shilei
- Abstract
Loading... -
+
P1.03-22 - MiR-125b Plays a Tumor Suppressor Role in Inflammation-Related Non-Small Cell Lung Cancer via Repressing IGF-1 Signal Pathway
16:45 - 18:00 | Presenter: Yanwei Zhang
- Abstract
Loading... -
+
P1.03-23 - The Molecular Landscape and Outcome of Chinese Patients with Non-Small Cell Lung Cancer Harboring NTRK1 Point Mutations: A Retrospective Study
16:45 - 18:00 | Presenter: Xiaohui Chen
- Abstract
Loading... -
+
P1.03-24 - TMPRSS4: A Novel Prognostic Biomarker and Therapeutic Target in NSCLC
16:45 - 18:00 | Presenter: Francisco Expósito
- Abstract
Loading... -
+
P1.03-25 - The Frequency and Prognosis of ATM Mutations in Chinese Non-Small-Cell Lung Cancer Patients
16:45 - 18:00 | Author(s): Chuanjun Han
- Abstract
Loading... -
+
P1.03-26 - Analysis of DDR2 Gene Aberrations in Chinese Non-Small-Cell Lung Cancer Patients and Evaluation of Their Prognosis
16:45 - 18:00 | Author(s): Jinhuo Lai
- Abstract
Loading... -
+
P1.03-27 - Somatic Mutations in BRCA2 Genes Are Associated with Prognosis in Chinese Non-Small-Cell Lung Cancer Patients
16:45 - 18:00 | Author(s): Jinhuo Lai
- Abstract
Loading... -
+
P1.03-28 - Association Between Molecular Characteristics of CTNNB1 Mutations and Prognosis in Patients with Nsclc in Chinese Patients
16:45 - 18:00 | Author(s): Jinhuo Lai
- Abstract
Loading... -
+
P1.03-29 - An Intronic Variant in EGFR Regulates GBAS Expression and Predicts Survival in Early-Stage Non-Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Mi Jeong Hong
- Abstract
Loading... -
+
P1.03-30 - The Number of Mutated Repair Genes as Predictor for Tumor Mutation Burden of Lung Adenocarcinoma
16:45 - 18:00 | Presenter: Yuqing Lou
- Abstract
Loading... -
+
P1.03-31 - Periostin is a Negative Prognostic Factor and Promotes Cancer Cell Proliferation in Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Toshimasa Okazaki
- Abstract
Loading... -
+
P1.03-32 - Molecular Characteristics and Prognosis FBXW7 Mutations in Chinese Non-Small-Cell Lung Cancer Patients
16:45 - 18:00 | Presenter: Chunwei Xu
- Abstract
Loading... -
+
P1.03-33 - Mutational Spectrum and Prognosis of Non-Small-Cell Lung Cancer Harboring MTOR Mutations in Chinese Population
16:45 - 18:00 | Presenter: Chunwei Xu
- Abstract
Loading... -
+
P1.03-34 - Combined Molecular and Radiological Evaluation Unveils Three Subtypes of Disease Progression to a Third Generation EGFR TKI
16:45 - 18:00 | Presenter: Yi-Chen Zhang
- Abstract
Loading...
-
+
P1.04 - Immunooncology (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 36
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.04-01 - Impact of Chromatin Remodeling Genes Including SMARCA2 and PBRM1 on Neoantigen and Immune Landscape of NSCLC
16:45 - 18:00 | Author(s): Lee Chun Park
- Abstract
Loading... -
+
P1.04-02 - Targeting Established Lung Cancer Through Combination of DNT Cellular Therapy with PD1 Checkpoint Blockade
16:45 - 18:00 | Presenter: Linan Fang
- Abstract
Loading... -
+
P1.04-03 - Suppressive Immune Cell Profiling in Patients with Non-Small Cell Lung Cancer.
16:45 - 18:00 | Presenter: Jiae Koh
- Abstract
Loading... -
+
P1.04-04 - Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity
16:45 - 18:00 | Author(s): Chen-Yi Chiang
- Abstract
Loading... -
+
P1.04-05 - Elucidating the Role of Leukocyte-Associated Immunoglobin-Like Receptor 2 (LAIR2) in Lung Cancer Development
16:45 - 18:00 | Presenter: Dalam Ly
- Abstract
Loading... -
+
P1.04-06 - Clinicopathological Analysis of Pulmonary Pleomorphic Carcinoma
16:45 - 18:00 | Presenter: Misa Noguchi
- Abstract
Loading... -
+
P1.04-07 - Pemetrexed Enhances Anti-Tumor Efficacy of PD-L1 blockade by Promoting Intra-Tumor Immune Response via Tumor and T Cell-Intrinsic Mechanisms
16:45 - 18:00 | Author(s): David Schaer
- Abstract
Loading... -
+
P1.04-08 - Co-Residence of Patient-Derived Immune Cells in Patient-Derived Xenografts from Lung Cancer Patients
16:45 - 18:00 | Presenter: Xingxiang Pu
- Abstract
Loading... -
+
P1.04-09 - Immunomodulatory Effects of Afatinib and Pembrolizumab in EGFR-Mutant NSCLC with Progression on Prior EGFR-TKI
16:45 - 18:00 | Presenter: Jonathan W Riess
- Abstract
Loading... -
+
P1.04-10 - The Importance of Suppressor and Cytotoxic T Lymphocyte Subsets and Cytotoxic Mechanisms in Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Akif Turna
- Abstract
Loading... -
+
P1.04-11 - Exploring the Germ-Line Contribution to Exceptional Response to PD-1/PD-L1 Inhibition in Patients with NSCLC by Whole Genome Sequencing
16:45 - 18:00 | Presenter: Megan Babette Barnet
- Abstract
Loading... -
+
P1.04-12 - Mass Spectrometry-Based Serum Proteomic Signature as a Potential Biomarker for Survival in NSCLC Patients with Immunotherapy
16:45 - 18:00 | Presenter: Young Kwang Chae
- Abstract
Loading... -
+
P1.04-13 - Combining Clinical and Genomic Data for Predicting Response to Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Michelle Chiu
- Abstract
Loading... -
+
P1.04-14 - HLA B44 Supertype Associated with Less Favorable Neoantigen Binding in Non-Small Cell Lung Cancer Treated with Immunotherapy
16:45 - 18:00 | Presenter: Amy Cummings
- Abstract
Loading... -
+
P1.04-15 - Computerized Tomography Texture Analysis as Biomarker of Benefit from Nivolumab in Advanced Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Carlo Genova
- Abstract
Loading... -
+
P1.04-16 - Comparison of Clinical Response to Checkpoint Inhibitors in Advanced NSCLC with High PD-L1 Expression Tested on Cytology Versus Biopsy Samples
16:45 - 18:00 | Presenter: Katie Guo
- Abstract
Loading... -
+
P1.04-17 - Tumour Burden as a Predictive Tool of Response to Immune Checkpoint Inhibitors (ICI) in Patients with Metastatic Non-Small-Cell Lung Cancer
16:45 - 18:00 | Presenter: Oded Icht
- Abstract
Loading... -
+
P1.04-18 - PD-L1 Expression and its Correlation with Tumor TNM Stage in Patients with Non-Small Cell Lung Cancer
16:45 - 18:00 | Presenter: Taewon Jang
- Abstract
Loading... -
+
P1.04-19 - Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios Predict Survival After Immunotherapy in Non-Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Michael Oh
- Abstract
Loading... -
+
P1.04-20 - Computational Biological Model Prediction of PD-L1 Expression and Immunotherapy Response for KRAS Mutated Lung Cancer Based on Co-Mutations
16:45 - 18:00 | Presenter: Sukhmani Kaur Padda
- Abstract
Loading... -
+
P1.04-21 - The Utility of PD-L1/CD8 Dual Immunohistochemistry for Prediction of Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Author(s): Matthew Rosenbaum
- Abstract
Loading... -
+
P1.04-22 - CD73 Immunohistochemical Expression in Malignant Cells and Correlation with Immune Infiltrate in Non-Small Cell Lung Carcinoma (NSCLC).
16:45 - 18:00 | Author(s): Ruth Salazar
- Abstract
Loading... -
+
P1.04-23 - Expression of Emerging Immunotherapy Targets in Early-Stage Squamous Lung Carcinoma
16:45 - 18:00 | Presenter: Hui Yu
- Abstract
Loading... -
+
P1.04-24 - Digital Core Needle-Biopsy to Assess PD-L1 Expression in Non-Small Cell Lung Cancer: Optimal Sampling and Need for Re-Biopsy
16:45 - 18:00 | Presenter: Alexander Haragan
- Abstract
Loading... -
+
P1.04-25 - The Implication of Frameshift Mutation Burden in Neoantigen and Immune Cell Landscape in Non-Small Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Presenter: Young Kwang Chae
- Abstract
Loading... -
+
P1.04-26 - Prospective Immuno-Biobank in NSCLC
16:45 - 18:00 | Author(s): Celine Py
- Abstract
Loading... -
+
P1.04-27 - Safety of Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) in the Real-Life Setting: A Single-Institution Experience from Argentina.
16:45 - 18:00 | Presenter: Maria Virginia Bluthgen
- Abstract
Loading... -
+
P1.04-28 - Baseline Markers of Inflammation and Outcome with Nivolumab in Pretreated Non Small Cell Lung Cancers: A Retrospective Study.
16:45 - 18:00 | Presenter: Alessandro Russo
- Abstract
Loading... -
+
P1.04-29 - Second or Third Line Nivolumab Versus First Line Nivolumab in Patients with Previously Treated Advanced Non Small Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Author(s): Elia Martinez Moreno
- Abstract
Loading... -
+
P1.04-30 - A Potential Effect of Diabetes Mellitus and Metformin Use on Efficacy of Immune Checkpoint Inhibitors (ICI)
16:45 - 18:00 | Presenter: Oded Jacobi
- Abstract
Loading... -
+
P1.04-31 - Efficacy and Tolerance of Immune-Checkpoint Inhibitors in EGFR, ALK/ROS 1 Non-Small-Cell-Lung-Cancer (NSCLC): GFPC 03-2016 IMAD Study
16:45 - 18:00 | Presenter: Olivier Bylicki
- Abstract
Loading... -
+
P1.04-32 - Phase I/II Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (pts) with Advanced NSCLC
16:45 - 18:00 | Presenter: Alberto A. Chiappori
- Abstract
Loading... -
+
P1.04-33 - Retrospective Descriptive Analysis of Metformin with Atezolizumab in Advanced Non-Small Cell Lung Cancer in The OAK Trial
16:45 - 18:00 | Presenter: Richard Pietras
- Abstract
Loading... -
+
P1.04-34 - Study on Treatment of Stage IV Solid Tumors with Mutant Neoantigen Specific T Cells
16:45 - 18:00 | Presenter: Song Qi
- Abstract
Loading... -
+
P1.04-35 - Quick Progression (QP) in Patients Treated by Nivolumab (IO) in 2nd Line or More for Non-Small Cell Lung Cancer: ERORECI Study (GFPC 2016-04)
16:45 - 18:00 | Presenter: Alain Vergnenegre
- Abstract
Loading... -
+
P1.04-36 - Tislelizumab Combined With Chemotherapy as First-Line Treatment in Chinese Patients With Advanced Lung Cancer
16:45 - 18:00 | Author(s): Jun Zhao
- Abstract
Loading...
-
+
P1.05 - Interventional Diagnostics/Pulmonology (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 23
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.05-01 - Incidence and Clinical Relevance of NSCLC Lymph Node Micro-Metastasis Detected by Staging EBUS-TBNA
16:45 - 18:00 | Presenter: Adam R Belanger
- Abstract
Loading... -
+
P1.05-02 - Endobronchial Ultrasound-Transbronchial Needle Aspiration for Lymphoma in Patients With Mediastinal Lymphadenopathy
16:45 - 18:00 | Presenter: Yu-Deok Choi
- Abstract
Loading... -
+
P1.05-03 - Significance of Lymph Node SUVmax In Predicting Nodal Metastasis By EBUS in Lung Cancer Patients
16:45 - 18:00 | Presenter: Michael Alexios Gulak
- Abstract
Loading... -
+
P1.05-04 - Cone-Beam CT Confirms the Status of Transbronchial Biopsy Under Virtual Bronchoscopic Navigation for Peripheral Lung Lesions
16:45 - 18:00 | Presenter: Naoya Kawakita
- Abstract
Loading... -
+
P1.05-05 - Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration for Suspected Malignancy; Current Status and Issues
16:45 - 18:00 | Presenter: Hidenao Kayawake
- Abstract
Loading... -
+
P1.05-06 - Bronchoscopic Image-Guided Microwave Ablation of Peripheral Lung Tumours – Early Results
16:45 - 18:00 | Presenter: Kelvin Kar Wing Lau
- Abstract
Loading... -
+
P1.05-07 - Clinical Significance of Pleural Indentation of Lung Adenocarcinoma Presented as Ground Glass Opacities
16:45 - 18:00 | Author(s): Hyung Joon Kim
- Abstract
Loading... -
+
P1.05-08 - Spread Through Air Spaces (STAS) in Invasive Mucinous Adenocarcinoma of the Lung: Incidence, Prognostic Impact, and Predictive Factors
16:45 - 18:00 | Presenter: Min A Lee
- Abstract
Loading... -
+
P1.05-09 - Dielectric Property Test for the Rapid Differential Diagnosis of Lung Nodules/Mass
16:45 - 18:00 | Presenter: Di Lu
- Abstract
Loading... -
+
P1.05-10 - Usefulness of Respiratory Dilatation Balloon in Tracheobronchial Stenosis Requiring Silicone Y-Stent Treatment
16:45 - 18:00 | Presenter: Shinjiro Mizuguchi
- Abstract
Loading... -
+
P1.05-11 - Role of EBUS-TBNA in Evaluation of Mediastinal Lymphadenopathy and Masses in Patients with Known or Suspected Extra-Pulmonary Malignancies
16:45 - 18:00 | Author(s): Aruna Nambirajan
- Abstract
Loading... -
+
P1.05-12 - 18F-FDG PET/CT Findings May Predict Postoperative Acute Exacerbation of Interstitial Pneumonia in Lung Cancer Patients
16:45 - 18:00 | Presenter: Hisashi Oishi
- Abstract
Loading... -
+
P1.05-13 - The Demonstration of the Possibility of the Pleura Cryo Biopsy – A Preliminary Report
16:45 - 18:00 | Presenter: Jaroslaw Pierog
- Abstract
Loading... -
+
P1.05-14 - Autofluorescence Mode of Thoracoscope Improves Visceral Pleural Invasion Diagnosis in Non-Small Cell Lung Cancer
16:45 - 18:00 | Author(s): Hiromitsu Takizawa
- Abstract
Loading... -
+
P1.05-15 - Benign Lung Nodule Resections in the Era of Advanced Imaging and Clinical Guidelines: Imaging Features and How we can Reduce the Resection Rate
16:45 - 18:00 | Presenter: Mohamed Sayyouh
- Abstract
Loading... -
+
P1.05-17 - Clinicopathological Characteristics of Primary Lung Cancers Associated with Emphysematous Bullae
16:45 - 18:00 | Presenter: Mikito Suzuki
- Abstract
Loading... -
+
P1.05-18 - Predictive Performance of Semi-Quantitative Metabolic Metrics on FDG-PET/CT for the Identification of EGFR Mutations
16:45 - 18:00 | Presenter: Taimei Tachibana
- Abstract
Loading... -
+
P1.05-19 - CT and PET/CT Parameters of Lepidic Predominant Pattern Lung Adenocarcinoma and Invasiveness on Pathology
16:45 - 18:00 | Presenter: Hiromitsu Takizawa
- Abstract
Loading... -
+
P1.05-20 - Therapeutic Condition of Photodynamic Therapy Using Taraporfin Sodium for Central Airway Stenosis
16:45 - 18:00 | Presenter: Takaaki Tsuchida
- Abstract
Loading... -
+
P1.05-21 - CT-Guided Biopsy of Lung Lesions with Outer Cannula Washing Cytology
16:45 - 18:00 | Presenter: Fumiyasu Tsushima
- Abstract
Loading... -
+
P1.05-22 - New Methods of Brachyradiotherapy Catheter Stabilization in the Airways
16:45 - 18:00 | Presenter: Jiri Votruba
- Abstract
Loading... -
+
P1.05-23 - Evaluation of the 8th Edition of the TNM Classification for Lung Cancer at a Single Institution
16:45 - 18:00 | Presenter: Jia Wang
- Abstract
Loading... -
+
P1.05-24 - Clinical Characteristics and Prognostic Analysis of Multiple Primary Malignant
Neoplasms in Patients with Lung Cancer16:45 - 18:00 | Presenter: Huijuan Wang
- Abstract
Loading...
-
+
P1.09 - Pathology (Not CME Accredited Session)
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 40
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.09-01 - PD-L1 Testing On NSCLC Cytology Samples in a UK Teaching Hospital
16:45 - 18:00 | Presenter: Haider Al-Najjar
- Abstract
Loading... -
+
P1.09-02 - PD-L1 Expression Pattern in Large Cell Neuroendocrine Carcinoma of the Lung: The GFPC 03-2017 "EPNEC" Study.
16:45 - 18:00 | Presenter: Dominique Arpin
- Abstract
Loading... -
+
P1.09-03 - Challenges in PD-L1 Immunoexpression in Liquid Based Cytology Samples of Advanced Stage Non-Small Cell Lung Carcinomas
16:45 - 18:00 | Presenter: Deepali Jain
- Abstract
Loading... -
+
P1.09-04 - Optimization of PD-L1 Testing Specimen Flow in the Greater Hamilton, Ontario Region
16:45 - 18:00 | Presenter: Rosalyn Juergens
- Abstract
Loading... -
+
P1.09-05 - Why Does PD-L1 (22C3) Expression Rate Show Difference Among Regional Hospitals?
16:45 - 18:00 | Presenter: Yuko Minami
- Abstract
Loading... -
+
P1.09-06 - The Incidence of PD-L1 in NSCLC and its Correlation with Driver Mutations in Turkish Patients; A Single Center Experience.
16:45 - 18:00 | Presenter: Buge Aysim Oz
- Abstract
Loading... -
+
P1.09-07 - PD-L1 Protein Expression is a Predictor of Benefit from Adjuvant Chemotherapy in Resected Non-Small Cell Lung Carcinoma
16:45 - 18:00 | Presenter: Naoki Yanagawa
- Abstract
Loading... -
+
P1.09-08 - Integrating NGS Information for Staging Multiple Lung Adenocarcinoma: A McGill University Health Centre Retrospective Study.
16:45 - 18:00 | Presenter: Ayesha Baig
- Abstract
Loading... -
+
P1.09-09 - Evaluation of a Novel ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in NSCLC Patients
16:45 - 18:00 | Presenter: Esther Conde
- Abstract
Loading... -
+
P1.09-10 - Targeted Sequencing of Pulmonary Enteric Adenocarcinoma Reveals Distinctive Mutation Profile from Conventional Type of Lung Adenocarcinoma
16:45 - 18:00 | Presenter: Likun Hou
- Abstract
Loading... -
+
P1.09-11 - Immunohistochemical Assessment of BRCA1 Associated Protein-1 (BAP1) in Pulmonary Mucoepidermoid Carcinomas
16:45 - 18:00 | Presenter: Deepali Jain
- Abstract
Loading... -
+
P1.09-12 - Simultaneous Platform of Genotyping EGFR, ALK, and ROS1 in Patients with NSCLC Highlights Correlation of ROS1 and PD-L1 Expression
16:45 - 18:00 | Presenter: Tae-Jung Kim
- Abstract
Loading... -
+
P1.09-13 - Detection of Actionable Mutations in Plasma cfDNA Samples From NSCLC Patients Using a Novel Amplicon-Based Firefly NGS Assay
16:45 - 18:00 | Presenter: Jiatao Lou
- Abstract
Loading... -
+
P1.09-14 - Analysis of Real-Word Mutations of Lung Cancer Driver Genes in 3081 Patients from China
16:45 - 18:00 | Author(s): Kewei Ma
- Abstract
Loading... -
+
P1.09-15 - Preliminary Experience with Liquid Biopsies in a Resource Constrained Setting and its Impact on Treatment Decision Making
16:45 - 18:00 | Presenter: Valliappan Muthu
- Abstract
Loading... -
+
P1.09-16 - Novel Somatic Gene Mutation of SLC17A9, Detected in Early-Stage Lung Adenocarcinoma
16:45 - 18:00 | Presenter: Shingo Sakashita
- Abstract
Loading... -
+
P1.09-17 - CTNNB1 (Beta-Catenin) Mutations in Non-Small Cell Lung Carcinoma: A Clinicopathological Study of 18 Cases
16:45 - 18:00 | Presenter: Vincent Thomas De Montpreville
- Abstract
Loading... -
+
P1.09-18 - 15 Cases of Clinical and Molecular Features Analysis in Pulmonary Adenoid Cystic Carcinoma
16:45 - 18:00 | Author(s): Wenxian Wang
- Abstract
Loading... -
+
P1.09-19 - Positive Correlation Between Whole Genomic Copy Number Variant Scoring and the Grading System in Lung Non-Mucinous Invasive Adenocarcinoma
16:45 - 18:00 | Presenter: Zheng Wang
- Abstract
Loading... -
+
P1.09-20 - Correlation Between Whole Genomic Copy Number Variant Scoring and Pathological Classification, Staging in Lung Non-Mucinous Adenocarcinoma
16:45 - 18:00 | Presenter: Zheng Wang
- Abstract
Loading... -
+
P1.09-21 - Circulating Tumor DNA Improves Genotypification and Detection of Targetable Alterations in Selected Lung Cancer Patients
16:45 - 18:00 | Presenter: Zyanya Lucia Zatarain-Barrón
- Abstract
Loading... -
+
P1.09-22 - Detection of ALK Gene Rearrangement in FFPE Tissues of Non-Small Cell Lung Cancer Using in Situ RNA Hybridization
16:45 - 18:00 | Author(s): Shafei Wu
- Abstract
Loading... -
+
P1.09-23 - Effect of Plasma Input on the Clinical Sensitivity of a Real-Time PCR Assay for the Detection Of EGFR Mutation in Plasma ctDNA From NSCLC Patients
16:45 - 18:00 | Author(s): Yuki Gao
- Abstract
Loading... -
+
P1.09-24 - The Effects of NLR and PLR of Effect on Prognosis in Patients with the Lung Cancer
16:45 - 18:00 | Presenter: Fazıl Aydın
- Abstract
Loading... -
+
P1.09-25 - Invasive Size (Not Total Size) Predicts Overall Survival in Invasive Mucinous Adenocarcinomas
16:45 - 18:00 | Presenter: Wei-Chin Chang
- Abstract
Loading... -
+
P1.09-26 - A Case Report of Discordant Markers of Lung Cancer Tumor Cells: An Unusual Immunophenotype of Uncertain Significance
16:45 - 18:00 | Presenter: Lisa Giscombe
- Abstract
Loading... -
+
P1.09-27 - Clear Cell Adenocarcinoma Subtype is an Independent Predictor of Better Survival in Patients with Lung Adenocarcinoma
16:45 - 18:00 | Presenter: Takefumi Komiya
- Abstract
Loading... -
+
P1.09-28 - Clinical Utility of Rapid Immunohistochemistry for Differentiation of Solitary Pulmonary Adenocarcinomas
16:45 - 18:00 | Presenter: Hayato Konno
- Abstract
Loading... -
+
P1.09-29 - In Situ Growth Pattern in Lung Adenocarcinoma Is Divisible into Distinct Categories with Divergent Biological and Survival Implications
16:45 - 18:00 | Author(s): David Moore
- Abstract
Loading... -
+
P1.09-30 - Heterotopic Expression of Ceruloplasmin in Lung Adenocarcinoma and its Possible Clinical Use as a Tumor Biomarker
16:45 - 18:00 | Presenter: Ryota Matsuoka
- Abstract
Loading... -
+
P1.09-31 - Preliminary Experience with Liquid Biopsies in a Resource Constrained Setting and Its Impact on Treatment Decision Making
16:45 - 18:00 | Presenter: Valliappan Muthu
- Abstract
Loading... -
+
P1.09-32 - Classification and Mutation Prediction from Non-Small Cell Lung Cancer Histopathology Images Using Deep Learning
16:45 - 18:00 | Presenter: Paolo Ocampo
- Abstract
Loading... -
+
P1.09-33 - Validity of Non-Small Cell Lung Cancer Not Otherwise Specified to Use Immunohistochemistry on Treatment Outcome
16:45 - 18:00 | Presenter: Takahiro Ota
- Abstract
Loading... -
+
P1.09-34 - Prognostic Impact of Invasive Size, Actual Tumor Size, and Mucinous Tumor Size in Invasive Mucinous Adenocarcinoma of the Lung.
16:45 - 18:00 | Presenter: Tomohito Saito
- Abstract
Loading... -
+
P1.09-35 - Clinical Impact of Systematic Inflammation and Histologic Grade in Non Small Cell Lung Carcinoma (NSCLC)
16:45 - 18:00 | Presenter: Nikolaos Tsoukalas
- Abstract
Loading... -
+
P1.09-36 - Clinical Significance of Cannabinoid Receptor CB2 Expression in Non Small Cell Lung Cancer (NSCLC)
16:45 - 18:00 | Presenter: Nikolaos Tsoukalas
- Abstract
Loading... -
+
P1.09-37 - Tumor Spread Through Air Spaces (STAS) in Stage I Lung Squamous Cell
16:45 - 18:00 | Presenter: Hironori Uruga
- Abstract
Loading... -
+
P1.09-38 - Pulmonary Epithelioid Hemangioendothelioma (EHE) with Von Recklinghausen Disease
16:45 - 18:00 | Presenter: Satoshi Yamamoto
- Abstract
Loading... -
+
P1.09-39 - Spread Through Air Spaces Predicts a Worse Survival in Patients with Stage I Adenocarcinomas > 2.0cm After Radical Lobectomy
16:45 - 18:00 | Presenter: Lin Yang
- Abstract
Loading... -
+
P1.09-40 - Metastatic Endometrial Sarcoma Presenting as a Spontaneous Pneumothorax and Masquerading as a Pulmonary Blastoma.
16:45 - 18:00 | Presenter: Giselle Alexandra Suero-Abreu
- Abstract
Loading...
first
prev
